The global hemophilia treatment market is expected to accumulate considerable returns in the coming years due to the growing cases of genetic abnormalities as well as the prevalence of hemophilia. Hemophilia is a rare bleeding condition that leads to prolonged bleeding after an injury or a surgery owing to a delay in blood clotting. As per the World Federation of Hemophilia, the global prevalence of hemophilia stood at 184,723 in 2016.